antiprogesterone therapy could slow CMT progression

[Guest guest]

Antiprogesterone hope for inherited neuropathy

Jane Bradbury

From The Lancent, January 1, 2004

There is no summary for this article. The text below is the first

paragraph of text within the article.

Antiprogesterone therapy could slow the progression of

Charcot-Marie-Tooth disease type 1A (CMT-1A), according to a team of

European researchers. In a proof-of-principle experiment, Klaus-Armin

Nave (Max-Planck Institute of Experimental Medicine, Go¨ttingen,

Germany) and colleagues describe how treatment of a rat model of CMT-1A

with a progesterone receptor antagonist improved the phenotype by

reducing overexpression of Pmp22, duplication of which underlies human

CMT-1A.